Abstract
Background: The management of the Metabolic Syndrome (MetS) includes lifestyle interventions (e.g. diet and exercise for weight reduction), as well as drug treatment to normalize blood pressure, high-density lipoprotein cholesterol, triglycerides and glucose values. Treatment of atherogenic dyslipidemia should comprise a primary therapeutic target since it is associated with an increased risk of cardiovascular disease.
Objective: To review the efficacy of the drugs available for the management of the dyslipidemia associated with MetS.
Methods: MEDLINE was searched up to May 10, 2009 for studies in English using the mesh – terms “metabolic syndrome”, “hypercholesterolemia”, “dyslipidemia”, “treatment”, “statins” and “cardiovascular disease” in various combinations to identify treatment strategies for the management of the dyslipidemia of the MetS.
Results/Conclusions: Several drugs have been described for the management of the dyslipidemia of the MetS, namely statins, fibrates, ezetimibe, niacin, bile acid sequestrants, cholesteryl ester transfer protein inhibitors, as well as combined treatment regimes. Although each of these may deal to some extent with some aspect of the dyslipidemia of the MetS compared with placebo, a direct comparison of all these agents has not been carried out. A head-to-head comparison between the suggested regimes could identify the mono- or combination therapy for the optimal management of dyslipidemia associated with MetS.
Keywords: Metabolic syndrome, dyslipidemia, statins, fibrates, ezetimibe, niacin, bile acid sequestrants
Current Vascular Pharmacology
Title: Targeting Dyslipidemia in the Metabolic Syndrome: An Update
Volume: 8 Issue: 4
Author(s): Kosmas I. Paraskevas, Gabriel Karatzas, Alkisti Pantopoulou, Dimitrios G. Iliopoulos and Despina Perrea
Affiliation:
Keywords: Metabolic syndrome, dyslipidemia, statins, fibrates, ezetimibe, niacin, bile acid sequestrants
Abstract: Background: The management of the Metabolic Syndrome (MetS) includes lifestyle interventions (e.g. diet and exercise for weight reduction), as well as drug treatment to normalize blood pressure, high-density lipoprotein cholesterol, triglycerides and glucose values. Treatment of atherogenic dyslipidemia should comprise a primary therapeutic target since it is associated with an increased risk of cardiovascular disease.
Objective: To review the efficacy of the drugs available for the management of the dyslipidemia associated with MetS.
Methods: MEDLINE was searched up to May 10, 2009 for studies in English using the mesh – terms “metabolic syndrome”, “hypercholesterolemia”, “dyslipidemia”, “treatment”, “statins” and “cardiovascular disease” in various combinations to identify treatment strategies for the management of the dyslipidemia of the MetS.
Results/Conclusions: Several drugs have been described for the management of the dyslipidemia of the MetS, namely statins, fibrates, ezetimibe, niacin, bile acid sequestrants, cholesteryl ester transfer protein inhibitors, as well as combined treatment regimes. Although each of these may deal to some extent with some aspect of the dyslipidemia of the MetS compared with placebo, a direct comparison of all these agents has not been carried out. A head-to-head comparison between the suggested regimes could identify the mono- or combination therapy for the optimal management of dyslipidemia associated with MetS.
Export Options
About this article
Cite this article as:
I. Paraskevas Kosmas, Karatzas Gabriel, Pantopoulou Alkisti, G. Iliopoulos Dimitrios and Perrea Despina, Targeting Dyslipidemia in the Metabolic Syndrome: An Update, Current Vascular Pharmacology 2010; 8 (4) . https://dx.doi.org/10.2174/157016110791330861
DOI https://dx.doi.org/10.2174/157016110791330861 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
Ischemic Cardiovascular Diseases: Mechanisms, Diagnosis and Therapy
Ischemic cardiovascular disease includes myocardial infarction, coronary atherosclerotic heart disease, angina pectoris, etc., constitute the leading cause of patient mortality by preventing tissues from getting sufficient oxygen and nutrients. Ischemic heart disease, as a clinical condition, is characterized by myocardial ischemia, causing an imbalance between myocardial blood supply and demand, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Editorial (Thematic Issue: All Roads of Renal Hypertension Lead to or Come from CKD)
Current Hypertension Reviews Platelets in Atherothrombosis: New and Evolving Roles
Current Pharmaceutical Design Calcium Related Genes in Dogs as Potential Cardiac Biomarkers for the Detection of Chronic Mitral Valve Disease
Recent Patents on Biomarkers Homocysteine and Hyperhomocysteinaemia
Current Medicinal Chemistry Reproductive Effects of Low-to-Moderate Medical Radiation Exposure
Current Medicinal Chemistry Enhancing Central Nervous System Endogenous GLP-1 Receptor Pathways for Intervention in Alzheimers Disease
Current Alzheimer Research Exercise Induced Cardioprotection: An Overview of a Unique Form of Preconditioning
Current Cardiology Reviews Nanotechnology for Nanomedicine and Delivery of Drugs
Current Pharmaceutical Design Nitric Oxide and its Antithrombotic Action in the Cardiovascular System
Current Drug Targets - Cardiovascular & Hematological Disorders Antibody-Mediated Endothelial Cell Damage Via Nitric Oxide
Current Pharmaceutical Design Type 2 Diabetes and Heart Failure: Challenges and Solutions
Current Cardiology Reviews Heart Failure Epidemiology: European Perspective
Current Cardiology Reviews A Review of Sirt1 and Sirt1 Modulators in Cardiovascular and Metabolic Diseases
Recent Patents on Cardiovascular Drug Discovery Endothelial Cells Facilitate Cell-Based Cardiac Repair: Progress and Challenge
Current Stem Cell Research & Therapy Mineralocorticoid Receptor Blockade in the Protection of Target Organ Damage
Cardiovascular & Hematological Agents in Medicinal Chemistry Stem Cells Therapies in Basic Science and Translational Medicine: Current Status and Treatment Monitoring Strategies
Current Pharmaceutical Biotechnology Arterial Stiffness and Cardiovascular Drugs
Current Pharmaceutical Design The Potential of Statins for Individualized Colorectal Cancer Chemoprevention
Current Drug Targets Clinical Applications and Biosafety of Human Adult Mesenchymal Stem Cells
Current Pharmaceutical Design Magnesium Lithospermate B Extracted from Salvia Miltiorrhiza, A Potential Substitute for Cardiac Glycosides
Mini-Reviews in Organic Chemistry